Literature DB >> 15222687

Proteomic analysis of multiple sclerosis cerebrospinal fluid.

B N Hammack1, K Y C Fung, S W Hunsucker, M W Duncan, M P Burgoon, G P Owens, D H Gilden.   

Abstract

Two-dimensional gel electrophoresis and peptide mass fingerprinting were used to identify proteins in cerebrospinal fluid (CSF) pooled from three patients with multiple sclerosis (MS) and in CSF pooled from three patients with non-MS inflammatory central nervous system (CNS) disorders. Resolution of CSF proteins on three pH gradients (3-10, 4-7 and 6-11) enabled identification of a total of 430 spots in the MS CSF proteome that represented 61 distinct proteins. The gels containing MS CSF revealed 103 protein spots that were not seen on control gels. All but four of these 103 spots were proteins known to be present in normal human CSF. The four exceptions were: CRTAC-IB (cartilage acidic protein), tetranectin (a plasminogen-binding protein), SPARC-like protein (a calcium binding cell signalling glycoprotein), and autotaxin t (a phosphodiesterase). It remains unknown whether these four proteins are related to the cause and pathogenesis of MS.

Entities:  

Mesh:

Year:  2004        PMID: 15222687     DOI: 10.1191/1352458504ms1023oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  45 in total

1.  Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord.

Authors:  Tong Liu; K Christian Donahue; Jun Hu; Michael P Kurnellas; Jennifer E Grant; Hong Li; Stella Elkabes
Journal:  J Proteome Res       Date:  2007-06-16       Impact factor: 4.466

Review 2.  The emerging role of vitamin D binding protein in multiple sclerosis.

Authors:  Giulio Disanto; Sreeram V Ramagopalan; Andrea E Para; Lahiru Handunnetthi
Journal:  J Neurol       Date:  2010-11-02       Impact factor: 4.849

3.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

4.  Alteration of DBP levels in CSF of patients with MS by proteomics analysis.

Authors:  Zhaoyu Qin; Yanjiang Qin; Shilian Liu
Journal:  Cell Mol Neurobiol       Date:  2008-09-19       Impact factor: 5.046

5.  Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS).

Authors:  Johannes Brettschneider; Helga Mogel; Vera Lehmensiek; Tino Ahlert; Sigurd Süssmuth; Albert C Ludolph; Hayrettin Tumani
Journal:  Neurochem Res       Date:  2008-05-15       Impact factor: 3.996

6.  Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke.

Authors:  Laure Allard; Natacha Turck; Pierre R Burkhard; Nadia Walter; Anna Rosell; Marianne Gex-Fabry; Denis F Hochstrasser; Joan Montaner; Jean-Charles Sanchez
Journal:  Biomark Insights       Date:  2007-04-19

7.  Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.

Authors:  Kaushal S Gandhi; Fiona C McKay; Eve Diefenbach; Ben Crossett; Stephen D Schibeci; Robert N Heard; Graeme J Stewart; David R Booth; Jonathan W Arthur
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

8.  Cerebrospinal fluid in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

9.  Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders.

Authors:  Abhilash Venugopal; Raghothama Chaerkady; Akhilesh Pandey
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

10.  Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients.

Authors:  Shumei Bai; Shilian Liu; Xuxiao Guo; Zhaoyu Qin; Banqin Wang; Xiaohong Li; Yanjiang Qin; Yi-Hsin Liu
Journal:  Mol Vis       Date:  2009-08-19       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.